Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations

被引:113
作者
Kassenbrock, CK [1 ]
Anderson, SM [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA
关键词
D O I
10.1074/jbc.M404114200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
c-Cbl down-regulates receptor tyrosine kinases by conjugating ubiquitin to them, leading to receptor internalization and degradation. The ubiquitin protein ligase activity of c-Cbl ( abbreviated as E3 activity) is mediated by its RING finger domain. We show here that the E3 activity of c-Cbl is negatively regulated by other domains present in the amino-terminal half of the protein ( the TKB and linker helix domains) and that this negative regulation is removed when the protein is phosphorylated on tyrosine residues. Protease digestion studies indicate that tyrosine phosphorylation alters the conformation of c-Cbl. We also show that mutation of certain conserved tyrosine residues to glutamate can constitutively activate the E3 activity of c-Cbl. In particular, a Y371E mutant shows constitutive E3 activity while retaining the ability to bind epidermal growth factor receptor ( EGFR). The Y371E mutant also has altered protease sensitivity from wild type, instead resembling the proteolytic pattern seen with tyrosine-phosphorylated c-Cbl. Mutation of the homologous tyrosine residue in Cbl-b to glutamate also leads to E3 activation while retaining EGFR-binding ability. These studies argue that Tyr-371 plays a key role in activating the E3 activity of c-Cbl and that the Y371E mutant may partially mimic phosphorylation at that site. However, Tyr-371 point mutants of c-Cbl are still able to undergo phosphorylation-induced E3 activation, and we show that Tyr-368 can also be phosphorylated in addition to Tyr-371, and contributes to activation.
引用
收藏
页码:28017 / 28027
页数:11
相关论文
共 29 条
[1]   TUMOR-INDUCTION BY ACTIVATED ABL INVOLVES TYROSINE PHOSPHORYLATION OF THE PRODUCT OF THE CBL ONCOGENE [J].
ANDONIOU, CE ;
THIEN, CBF ;
LANGDON, WY .
EMBO JOURNAL, 1994, 13 (19) :4515-4523
[2]   Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line [J].
Bisson, SA ;
Ujack, EE ;
Robbins, SM .
ONCOGENE, 2002, 21 (23) :3677-3687
[3]  
BLAKE TJ, 1991, ONCOGENE, V6, P653
[4]   The ubiquitin-proteasome pathway: on protein death and cell life [J].
Ciechanover, A .
EMBO JOURNAL, 1998, 17 (24) :7151-7160
[5]   The ubiquitin system [J].
Hershko, A ;
Ciechanover, A .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :425-479
[6]   The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase [J].
Joazeiro, CAP ;
Wing, SS ;
Huang, HK ;
Leverson, JD ;
Hunter, T ;
Liu, YC .
SCIENCE, 1999, 286 (5438) :309-312
[7]   Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor [J].
Kassenbrock, CK ;
Hunter, S ;
Garl, P ;
Johnson, GL ;
Anderson, SM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :24967-24975
[8]   cbl-3: a new mammalian cbl family protein [J].
Keane, MM ;
Ettenberg, SA ;
Nau, MM ;
Banerjee, P ;
Cuello, M ;
Penninger, J ;
Lipkowitz, S .
ONCOGENE, 1999, 18 (22) :3365-3375
[9]  
KEANE MM, 1995, ONCOGENE, V10, P2367
[10]   Substrate targeting in the ubiquitin system [J].
Laney, JD ;
Hochstrasser, M .
CELL, 1999, 97 (04) :427-430